Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) led to significant improvements in cognition in patients with…
Articles by Patricia Inacio, PhD
ProMIS Neurosciences will advance the development of PMN310, its manmade antibody designed to target the toxic forms of amyloid beta…
Longeveron’s Lomecel-B, an investigational bone marrow-derived medicinal signaling cell (MSC), showed an ability to slow cognitive decline and the loss…
NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people…
Cognito Therapeutic’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s…
Fujirebio Diagnostics has submitted a premarket notification — also known as a 510(k) — to the U.S. Food and…
Biogen and Eisai are seeking approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease in Japan, the…
AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Axsome Therapeutics‘ AXS-05, an…
The U.S. Food and Drug Administration (FDA) has approved Tauvid (flortaucipir F18) as an imaging radiotracer agent — a radioactive…